Eli Lilly and Company is a leading, innovation-driven corporation committed to developing a growing portfolio of best-in-class and first-in-class pharmaceutical products that help people live longer, healthier and more active lives. Lilly products treat depression, schizophrenia, attention-deficit hyperactivity disorder, diabetes, osteoporosis and many other conditions. They are committed to providing answers that matter - through medicines and information - for some of the world's most urgent medical needs.Greater China
A pioneering initiative to treat multi-drug resistant tuberculosis (MDR-TB), one of the deadliest public health threats in the world. In collaboration with the World Health Organization (WHO), the U.S. Department of Health and Human Services Centers for Disease Control and Prevention, Brigham and Women's Hospitals of Harvard Medical School, and Purdue University, Lilly is providing low-cost antibiotics, training for international medical personnel, and technology to enable the manufacture of products for treatment in China, India, and South Africa.
Lilly in the UK
Today, Lilly employs over 2,400 people in the UK. Lilly invests the highest proportion of sales back into research and development in the sector, just under 20%. In 2004, Lilly invested £76 million in R&D in the UK alone. Lilly´s most successful medicine, Zyprexa®, was discovered in the UK at the research facility in Windlesham, Surreyă€‚ Lilly´s manufacturing facility in Speke, Liverpool is the largest bulk-biotechnology facility in the UK.
Innovation in Medicine
10 to 12 years to develop – at a cost of around £500 million (total life cycle = approx 20 years). On average, only one in 10,000 compounds will pass successfully through the screens and trials necessary for regulatory approval. The pharmaceutical industry invests £3.1 billion in R&D each year, more than £8 million every dayă€‚ Pharmaceutical companies carry out almost a quarter of all UK industrial R&D.
Eli Lilly Asia, Inc. (Hong Kong) is responsible for the marketing and sales of Lilly's pharmaceutical products to the Hong Kong market. Lilly Hong Kong is part of the Greater China Region, which is headquartered in Shanghai.
Lilly will boost its R&D in China, especially on biological pharmaceuticals through cooperation with other companies. Lilly's current R&D focuses mainly on chemical pharmaceuticals, through cooperation with its Chinese partner Shanghai ChemExplorer. The pharmaceutical giant has 230 scientists working in China, accounting for 20% of its total number of scientists; the China-based R&D team is the US-based firm's largest R&D group overseas.
Eli Lilly Suzhou Pharmaceutical Co. Ltd. is the only wholly-owned company in China of Eli Lilly USA. This company was set up in 1996 and approved GMP by SFDA in 1998.It covers 30,000 square meters. The total investment of this company is 90 million dollars.
Until now, Eli Lilly has nearly 30 offices and more than 800 staff in China.
Eli Lilly Asia, Inc.
31st Floor - Harbor Ring Plaza
18 Xi Zhang Middle Road
Shanghai 200001, P.R. China
Facts and Figures
A heritage more than 130 years strong: company founded on May 10, 1876
Approximately 41,500 employees worldwide
Approximately 8,262 employees engaged in research and development
Clinical research conducted in more than 50 countries
Research and development facilities located in 9 countries
Manufacturing plants located in 13 countries
Products marketed in 143 countries
Byetta®, a first in a new class of medicines known as incretin mimetics to treat type 2 diabetes
Cymbalta®, for major depressive disorder and diabetic peripheral neuropathic pain
Alimta®, the first and only chemotherapy regimen approved by the FDA to treat patients with malignant pleural mesothelioma who are not candidates for surgery
Symbyax®, for bipolar depression
Cialis®, a distinctive new treatment for erectile dysfunction from the Lilly ICOS joint venture
Strattera®, the first FDA-approved nonstimulant, noncontrolled medication for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and adults
Forteo®, first-in-class medicine for osteoporosis patients that stimulates new bone formation
Xigris®, the first treatment approved for adult severe-sepsis patients at a high risk of death
Evista®, the first in a new class of drugs for the prevention and treatment of postmenopausal osteoporosis
Zyprexa®, breakthrough product for schizophrenia and acute mania associated with bipolar disorder
Humalog®, a fast-acting insulin product
Gemzar®, for pancreatic and non-small-cell lung cancer, one of the world's best-selling oncology agents
Humatrope®, therapy for growth hormone deficiency
Prozac®, which revolutionized the treatment of depression
Humulin®, human insulin, the first human-health-care product created by biotechnology
Ceclor®, which became the world's top-selling oral antibiotic
Iletin®, the first commercially available insulin product, in 1923
Eli lily research center in China
The world-leading pharmaceutical company, US-based Eli Lilly, set up its the 4,000-sq-mChina research lab in the Zhangjiang Hi-Tech Park in August 2005, built in co-operation with its Chinese partner Shanghai ChemExplorer, a chemical research company.
Eli Lilly & Company, one of the world's leading pharmaceutical companies, expects to double or triple its sales revenues in China in five years by investing more in R&D. China is expected to be among Lilly's top 10 markets, although it now contributes only 1% of the company's global sales.
Lilly boost its R&D in the country, especially on biological pharmaceuticals through cooperation with other companies. Lilly's current R&D focuses mainly on chemical pharmaceuticals, through cooperation with its Chinese partner Shanghai ChemExplorer. The pharmaceutical giant has 230 scientists working in China, accounting for 20% of its total number of scientists; the China-based R&D team is is the US-based firm's largest R&D group overseas.
Lilly's R&D in the country targets three most common diseases among the Chinese: neuropathy, diabetes and cancer. In addition, it will set up 10 training centers in China for doctors and nurses treating diabetes patients. The company launched nine new medicines in China during the past year and a half, and the number of its products in the local market has doubled during the past three years.
Lilly globally spends approximately 20% of its revenues on developing new drugs, higher than the industry's average of 15%. Thanks to the constant investment in pharmaceutical innovations, Lilly are "very unique in that we do not have the problem of patent expiration until 2011," and thus the company will be able to maintain a higher growth than the industry average, said Taurel.
In comparison, nearly half of the patented medicines developed by the world's major pharmaceutical companies are facing challenges from patent expiration, mostly before 2007. Local generic pharmaceutical firms can legally produce these medicines after the patents expire. Lilly has recently agreed to transfer its antibiotics manufacturing technology to leading Chinese company Hisun Pharmaceutical Co Ltd. The move is part of Lilly's US$70-million global initiative to address multi-drug resistant tuberculosis, in partnership with the World Health Organization.